Back to Search Results

Vitamin D supplementation for prevention of cancer: The D2d cancer outcomes (D2dCA) study.

Division of General Internal Medicine, 200 Morris Street, 3(rd) Floor, Box 104427, Durham, NC 27701, USA. Electronic address: ranee.chatterjee@duke.edu. Cancer Center, Tufts Medical Center, 800 Washington St, Box 245, Boston, MA 02111, USA. Electronic address: JErban@tuftsmedicalcenter.org. Division of Endocrinology, Tufts Medical Center, 800 Washington Street, Box 268, Boston, MA 02111, USA. Electronic address: pfuss@tuftsmedicalcenter.org. Division of General Internal Medicine, 200 Morris Street, 3(rd) Floor, Box 104427, Durham, NC 27701, USA. Electronic address: rowena.dolor@duke.edu. Kaiser Permanente Center for Health Research NW, 3800 N Interstate, Portland, OR 97229, USA. Electronic address: Erin.s.leblanc@kpchr.org. Kelly Government Services for the National Institute of Diabetes and Digestive and Kidney Diseases, 6701 Democracy Boulevard, Room 6107, Bethesda, MD 20817, USA. Electronic address: statenm@niddk.nih.gov. Spaulding Rehabilitation Network, 300 1(st) Ave, Charlestown, MA 02129, USA. Electronic address: prsheehan@partners.org. Division of Endocrinology, Tufts Medical Center, 800 Washington Street, Box 268, Boston, MA 02111, USA. Electronic address: apittas@tuftsmedicalcenter.org.

Contemporary clinical trials. 2019;:62-70
Full text from:

Other resources

Abstract

Evidence on biological plausibility from mechanistic studies and data from observational studies suggest that vitamin D may be linked to risk of several types of cancer. However, evidence from clinical trials evaluating the effect of vitamin D supplementation on cancer risk is limited. The Vitamin D and Type 2 Diabetes (D2d) study is a multi-center, randomized, placebo-controlled clinical trial conducted to examine the causal relationship between oral vitamin D supplementation and development of diabetes among overweight adults with prediabetes. The D2d study provides a unique opportunity to assess the effect of vitamin D supplementation at a higher dose (4000 IU/day) than has been used in other clinical trials with cancer outcomes, in a population at higher than average risk for cancer. This paper provides: Krishnan and Feldman (2011) a) baseline characteristics of the D2d population included in the D2d cancer outcomes secondary study (D2dCA) and comparison to other large trials of vitamin D supplementation and cancer risk; Leyssens et al. (2013) b) description of data that are being collected during the trial and the planned statistical analyses to test whether vitamin D supplementation at a dose of 4000 IU/day has an effect on incident cancer overall, on incidence of certain types of cancer, and on incidence of precancerous lesions. Results of D2dCA will help guide future research and clinical recommendations related to vitamin D and cancer risk.